Oncological and Functional Outcomes for Men Undergoing Salvage Whole-gland Cryoablation for Radiation-resistant Prostate Cancer.

There is no consensus on the optimal approach for salvage local therapy in radiation-resistant/recurrent prostate cancer (RRPC).

To investigate oncological and functional outcomes for men treated with salvage whole-gland cryoablation (SWGC) of the prostate for RRPC.

We retrospectively reviewed our prospectively collected cryosurgery database between January 2002 and September 2019 for men who were treated with SWGC of the prostate at a tertiary referral center.

SWGC of the prostate.

The primary outcome was biochemical recurrence-free survival (BRFS) according to the Phoenix criterion. Secondary outcomes included metastasis-free survival, cancer-specific survival, and adverse events.

A total of 110 men with biopsy-proven RRPC were included in the study. Median follow-up for patients without biochemical recurrence (BCR) after SWGC was 71 mo (interquartile range [IQR] 42.3-116). BRFS was 81% at 2 yr and 71% at 5 yr. A higher prostate-specific antigen (PSA) nadir after SWGC was associated with worse BRFS. The median International Index of Erectile Function-5 score was 5 (IQR 1-15.5) before SWGC and 1 (IQR 1-4) after SWGC. Stress urinary incontinence, strictly defined as the use of any pads after treatment, was 5% at 3 mo and 9% at 12 mo. Clavien-Dindo grade ≥3 adverse events occurred in three patients (2.7%).

In patients with localized RPPC, SWGC achieved excellent oncological outcomes with a low rate of urinary incontinence, and represents an alternative to salvage radical prostatectomy. Patients with fewer positive cores and lower PSA tended to have better oncological outcomes following SWGC.

For men with prostate cancer that persists after radiotherapy, a freezing treatment applied to the whole prostate gland can achieve excellent cancer control. Patients who did not have elevated prostate-specific antigen (PSA) at 6 years after this treatment appeared to be cured.

European urology oncology. 2023 Mar 06 [Epub ahead of print]

Wei Phin Tan, Srinath Kotamarti, Alexandria Ayala, Rachael Mahle, Emily Chen, Rohith Arcot, Andrew Chang, Zoe Michael, Denis Seguier, Thomas J Polascik

Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC, USA; Duke University School of Medicine, Durham, NC, USA; Department of Urology, New York University Langone Health, New York, NY, USA., Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC, USA., Duke University School of Medicine, Durham, NC, USA., Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC, USA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC, USA. Electronic address: .